dr. hahn discusses abiraterone versus docetaxel in prostate cancer
Published 6 years ago • 324 plays • Length 1:32Download video MP4
Download video MP3
Similar videos
-
0:20
copy of dr. hahn discusses abiraterone versus docetaxel in prostate cancer
-
0:45
dr. hahn on patients with prostate cancer whom neither docetaxel or abiraterone is an option
-
1:54
dr. hahn on patient selection for abiraterone versus docetaxel in mhspc
-
1:41
dr. oh on abiraterone versus docetaxel in prostate cancer
-
1:53
abiraterone vs docetaxel for metastatic castrate resistant prostate cancer
-
1:22
dr. bryce on the use of abiraterone versus docetaxel in patients with prostate cancer
-
1:37
dr. oh discusses the use of abiraterone and docetaxel in prostate cancer
-
1:19
comparing abiraterone and docetaxel in prostate cancer treatment
-
1:24
dr. higano on docetaxel for hormone-sensitive prostate cancer
-
1:26
dr. oh discusses choosing abiraterone in prostate cancer
-
1:11
dr. burgess on the synergy between abiraterone and adt in prostate cancer
-
1:17
dr. oh on the safety profile of docetaxel in prostate cancer
-
1:05
dr. agarwal on candidates for docetaxel versus abiraterone and prednisone
-
5:16
exciting advances in systemic therapy for prostate cancer: docetaxel and abiraterone
-
1:43
dr. oh on the role of docetaxel in metastatic hormone-sensitive prostate cancer
-
2:31
dr. tagawa on abiraterone and docetaxel in mcrpc
-
1:47
dr. oh on remaining challenges with docetaxel in prostate cancer
-
0:59
dr. crawford on abiraterone versus enzalutamide in prostate cancer
-
0:41
dr. daniel petrylak discusses the future of abiraterone acetate